Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity's Supplemental New Drug Application For REVTORPYK Accepted for FDA Review To Treat Hormone Receptor Positive
HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $150
Celcuity Inc. (CELC) Q3 2026 Earnings Call Transcript
Celcuity (CELC) Q3 2026 Earnings Call Transcript
Celcuity Inc. Q3 2026 Earnings Call Summary
Guggenheim Maintains Buy on Celcuity, Lowers Price Target to $169
Celcuity Inc (CELC) Q3 2026 Earnings Call Highlights: Revtorpic's Strong Launch Momentum Meets ...
What Celcuity (CELC) Said on Its Q3 Earnings Call
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Celcuity Q3 2026 Earnings Call Transcript
Celcuity Q3 Adj. EPS $(1.21) Beats $(1.43) Estimate, Sales $0.00 Miss $1.563M Estimate
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140
TD Cowen Reiterates Buy on Celcuity, Announces $145 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.